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ACE2 purified from failing human heart was found to form a complex with integrin h1 by immunoprecipitation, Western blotting, activity
assay, and ESI tandem mass spectroscopy. The ACE2/integrin complex showed a Km of 6.8 AM and a Vmax of 2.13 pmol/min/Al purified
enzyme. Activity was optimal at pH 7.5 with Ang II substrate.
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verting enzyme (ACE), ACE2 or ACEH [1,2], was shown to
hydrolyze Ang I to Ang-(1–9) and Ang II to Ang-(1–7)
when expressed as a recombinant protein. We previously
demonstrated a significant increase in ACE2 activity in
failing human heart ventricles, and found that ACE2 was
a major pathway for Ang-(1–7) formation from Ang II in
the intact human heart [3,4]. The ACE2 knockout mouse
was shown to have impaired cardiac contractility suggesting
a potential counter-regulatory role for ACE2 in the patho-
genesis of heart failure [5]. In this study we purified ACE2
from failing human heart and discovered its unanticipated
association with integrin h1. The protein complex showed
high catalytic activity with Ang II as substrate, but, in
contrast to recombinantly expressed ACE2, did not hydro-
lyze Ang I.
ACE2 was purified from a solubilized failing human
heart left ventricular membrane fraction with ammonium
sulfate precipitation followed by a series of chromatograph-
ic steps including Q-sepharose, Phenyl-Sepharose, DEAE-
sepharose, SP-Sepharose and Suprose HR. ACE2 activity
was tracked as previously described [3].The ACE2 specific
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Rad DC protein assay kit. The purification strategy is
summarized in Table 1. The pH effect of the purified
enzyme complex was measured with a universal buffer
containing 50 mM Tris–Maleic acid, 50 mM NaCl, and 1
AM ZnCl2 with pH range from 5.4 to 8.6. Michaelis–
Menten kinetics were determined with 3H-Ang II. This
study was performed under the auspices of an Institutional
Review Board approved protocol.
Sequencing with tandem mass spectroscopy was per-
formed at the University at Albany Mass Spectroscopy
Facility (Rensselaer, NY). The tryptic peptides were ana-
lyzed and sequenced on an LC-ESI-MS-MS system (Micro-
mass Q-Tof 2, Micromass, UK).
Immunoprecipitation was performed as follows: Protein
G sepharose beads (Amersham) were washed with assay
buffer (50 mM Tris–Cl pH 7, 50 mM NaCl, 1 AM ZnSO4).
Protein G (50 Al) was added to 400 Al of the Q-sepharose
ACE2 fraction or solubilized membrane preparations of
failing human heart to ‘‘clear’’ the samples. Each sample
was centrifuged at 12k g for 30 s and the supernatant
transferred to a new 1.5-ml Eppendorf centrifuge tube.
Integrin h 1 monoclonal antibody (P5D2, 20 Ag, 1 Ag/5
Al, Santa Cruz Biotechnology) was added to the cleared
supernatant. Incubation with gentle mixing at 4 jC was
performed for 2 h. Protein G was added and the sample
mixed gently for 2 h at 4 jC. The sample was centrifuged at
Table 1
Purification of the ACE2/integrin complex from failing human heart
Step Total
protein
(mg)
Activity
(fmol/min)
Specific
activity
(fmol/min/Ag)
Yield
(%)
Fold
enrichment
0.6%TX100
extraction
512 0.683 0.0958 100 1
AS Pellet 198 1.350 0.294 38.7 3.1
Q-sepharose 39.2 1.420 0.579 7.7 6
First Phenyl-
sepharose
7 2.230 1.730 1.4 18
DEAE 1.84 0.923 4.40 0.36 45.8
Second Phenyl-
sepharose
0.928 2.800 6.00 0.18 62.6
SP-sepharose 0.01 1.300 86.80 0.002 906
SEC 0.003 1.400 311 0.0006 3247
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pellet washed three times with 1-ml assay buffer to ensure
that there was no residual non-precipitated material from theFig. 1. Tandem mass spectroscopy performed on the SEC fraction containing 300
addition to ACE2. (A) CID fragmentation of tryptic peptide demonstrating the seq
tryptic peptide demonstrating the sequence WDTQENPIYK from integrin h1 (NMsupernatant. The supernatant and pellet were saved for
immunoblotting and for measurement of ACE2 activity.
To measure ACE2 activity in the pellet, the assay was
performed as usual except that the incubation tube was
vortexed every 2 min during the 20-min incubation to keep
the protein G-immunocomplex in suspension.
After each purification step, an aliquot of the preparation
was analyzed by 10% SDS-PAGE gel according to the
method of Laemmli [7]. Blotting was with either the anti
ACE2 antibody (a kind gift of Dr. Susan Acton, Cambridge,
MA) or the anti-integrin h 1D antibody (a kind gift from Dr.
Joseph C. Loftus, Scottsdale, AZ). Bound antibody was
detected using an enhanced chemiluminescence system
(Amersham Pharmacia Biotech, NJ). In the case of ACE2,
Western blot incubations were performed with scrambled
peptide, TFDDPSVELVAHSHEPNYCP, or blocking pep-
tide, EPVPHDETYCDPASLFHVSN, to prove the specific-
ity of the antibody (Biopeptide, San Diego, CA).0-fold purified ACE2 complex demonstrated the presence of integrin h1 in
uence ISFNFFVTAPK from ACE 2 (AB046569). (B) CID fragmentation of
_033668).
 Fig. 3. Immunoprecipitation of the ACE2/integrin complex purified from
human heart. The immunoprecipitation was performed with the anti-
integrin h1 antibody, P5D2. (A) Q-sepharose-purified ACE2 was
immunoprecipitated with P5D2. Lane 1: Western blot with the anti-ACE2
antibody in the presence of scrambled peptide; 2: Western blot with anti-
ACE2 antibody in the presence of blocking peptide showing specificity of
the ACE2 antibody; 3: Western blot with the anti-integrin h1D specific
antibody showing the presence of integrin h1D in the immunoprecipitate.
(B) Direct immunoprecipitation of a solubilized membrane preparation
from a failing human heart right ventricle. Lanes 1 and 3: supernatant after
immunoprecipitation. Lanes 2 and 4: immunoprecipitate with the P5D2
antibody. Western blots were performed with either the ACE2 antibody
(lanes 1 and 2) or the anti-integrin h1D antibody (lanes 3 and 4).
Immunoprecipitation with the anti-integrin antibody pulled down both
ACE2 and integrin h 1D from a failing human heart membrane preparation.
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enrichment was achieved for the ACE2 complex. When
fractions from each step were analyzed by Coomassie blue-
stained SDS-PAGE, a band of 130 kDa was the major band
remaining at the end of the purification. ESI tandem mass
spectroscopy confirmed the presence of ACE2 as well as
integrin h1 in this band (Fig. 1). Western blot analysis with
the anti-ACE2 antibody and the anti-integrin h1D antibody
demonstrated the co-purification of ACE2 and integrin h1D
(Fig. 2). Immunoprecipitation experiments confirmed that
ACE2 and integrin h1D formed a protein complex (Fig. 3).
In addition, ACE2 activity could be measured in the
immunoprecipitate that used an anti-integrin h1 antibody
to capture the protein complex (Fig. 4). Kinetic analysis
with the purified ACE2/integrin complex demonstrated an
apparent Km of 6.12 AM for [tyrosyl-3,5-3H] Angiotensin II
and a Vmax of 2.13 pmol/min/Al. The enzyme activity was
maximal at pH 7.5. Interestingly, when [125I]-Angiotensin I
and [125I]-Bradykinin were used as substrates, there was no
measurable peptidase activity. Instead, Ang I inhibited the
enzyme with an IC50 of 43.6 AM. Bradykinin was a less
potent inhibitor (IC50 = 2.64 mM).
The major findings of this study are that ACE2 purified
from failing human heart interacted with integrin h1, and
hydrolyzed Ang II, but not Ang I. While there are previous
reports of interactions of matrix metalloproteinases and
ADAMS with integrins, this study is the first to report an
interaction between ACE2 and an integrin protein [8–13].
Historically integrins were first shown to play an impor-
tant role in cell–matrix adhesion, and function to transduce
changes in physical strain in the extracellular matrix to
intracellular signals [14]. Several integrin binding motifs
have been described, the most well known being the RGD
motif.
ACE2 contains two integrin binding domains: an RGD at
position 204–206, and the sequence RKKKNKAR in the
cytoplasmic tail at its C-terminus, which is highly homol-
ogous to the integrin binding domain of the HIV Tat protein
(RKKRRQRRR) [15]. Collectrin, a truncated form of
ACE2, has no intrinsic angiotensinase activity but has been
found to play a role in renal organogenesis. Collectrin also
contains an RKNK motif [16]. It is possible that bothFig. 2. Western blots of the ACE 2/integrin complex. (A) Western blot with
the ACE2 antibody. (B) Western blot with the anti-integrin h1 D antibody.
Lane 1, extraction; lane 2, Q-sepharose; lane 3, phenyl-sepharose; lane 4,
DEAE-sepharose; lane 5, SP-sepharose. Each lane was loaded with 2.5 Ag
of protein.collectrin and ACE2 have effects on integrin signaling
independent of angiotensinase activity. Interactions of Ang
II and integrins have been previously reported. Ang II has
been shown to induce h1-integrin-mediated adhesion and
spreading in human vascular smooth muscle cells [17].
Function blocking antibodies to avh3 and a5h1 prevented
Ang II-induced contraction of aortic rings [18]. However,
there are no previous reports of a direct or indirect interac-Fig. 4. HPLC chromatograms showing ACE2 activity in the anti-integrin
h1 antibody immunoprecipitate (lanes 1 and 2 are duplicate experiments).
Lanes 3 and 4 show chromatograms of residual ACE2 activity in the
supernatant after immunoprecipitation. Lane 5 shows that all 125I-Ang-(1-7)
forming activity in the immunoprecipitate was inhibited by the ACE2
specific inhibitor C16. These data indicate that ACE2 formed a complex
with integrin h1D, and that ACE2 in this complex was catalytically active.
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ACE2 was first reported to hydrolyze Ang I to Ang-(1–
9). Subsequently, it was found that ACE2 hydrolyzed Ang II
to Ang-(1–7) at a much higher rate than Ang I to Ang-(1–
9) [19]. The enzyme kinetics we found for the ACE2/
integrin complex purified from human heart were similar
to those reported for the recombinantly expressed form of
ACE2 when Ang II was used as substrate. However, the
purified ACE2 integrin protein complex did not metabolize
Ang I. It is important to keep in mind that the recombinantly
expressed form of ACE2 was specifically engineered to
result in a truncated form of ACE2 that did not contain the
transmembrane or cytosolic domains of the protein. This
fact may explain some of the differences in enzyme kinetics
and substrate specificities that we observed between ACE2
purified from human heart and the recombinantly expressed
ACE2. It is also possible that some of the observed differ-
ences were the result of the interaction between ACE2 and
integrins. Because the a5h1A and a7h1D integrin hetero-
dimers have differential expression in myocytes vs. non-
myoctyes, the relative affinity of ACE2 for each of these
heterodimers may have important implications for the lo-
calization of ACE2 in cardiac cells [14].
In conclusion, this study is the first to report the novel
interaction between ACE2 and an integrin protein. It is
proposed that the interaction between ACE2 and integrin
h1 is a regulatory mechanism for ACE2 activity and
localization.References
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